Business Context and Reporting Period
This Form 6-K filing by NLS Pharmaceutics Ltd. (NLS) is dated October 9, 2025. The report discloses a Merger Agreement entered into on November 4, 2024, between NLS, its wholly owned subsidiary NLS Pharmaceutics (Israel) Ltd., and Kadimastem Ltd. (TASE: KDST). Under the agreement, Kadimastem will merge into the subsidiary, with Kadimastem shareholders receiving NLS common shares. The filing provides financial data for Kadimastem for the six months ended June 30, 2025, and the years ended December 31, 2024 and 2023, alongside NLS's pro forma combined statements.
Key Financial Metrics
The filing text references attached exhibits containing specific financial data but does not explicitly state the numerical values for revenue, profit, cash flow, margins, debt, or liquidity within the body of this report.
- Revenue, Profit, and Margins: Not provided in the text; contained in attached Exhibits 99.1 and 99.2.
- Cash Flow and Liquidity: Not provided in the text; contained in attached Exhibits 99.1 and 99.2.
- Debt: Not provided in the text; contained in attached Exhibits 99.1 and 99.2.
- Pro Forma Data: Unaudited pro forma condensed combined financial statements for NLS are included in Exhibit 99.3 for the six months ended June 30, 2025, but specific figures are not listed in the summary text.
Material Changes
The primary material change disclosed is the execution of the Merger Agreement with Kadimastem Ltd. This transaction represents a significant corporate restructuring where Kadimastem will cease to exist as a separate entity and become a subsidiary of NLS. The filing includes interim and audited financial statements for Kadimastem to facilitate the evaluation of this transaction.
Guidance, Outlook, and Risks
The filing does not contain explicit management commentary, forward-looking guidance, or a detailed risk factor section within the provided text. The primary contingency noted is the completion of the Merger, which is subject to the terms of the Merger Agreement signed in November 2024. The exchange ratio for Kadimastem shares to NLS shares is determined by the terms of that agreement.
Investor Verification Checklist
- Review Exhibit 99.1 for Kadimastem's specific interim financial performance for the six months ended June 30, 2025.
- Examine Exhibit 99.2 for Kadimastem's audited financial results for the fiscal years 2023 and 2024.
- Analyze Exhibit 99.3 for NLS's pro forma combined financial statements to understand the post-merger financial position.
- Verify the specific share exchange ratio and closing conditions detailed in the Merger Agreement referenced in the filing.
- Confirm the regulatory approval status required for the merger to become effective.